NorthStar Medical Radioisotopes and the Low Institute for Therapeutics (LIFT), a non-profit clinical research organization, have entered a strategic collaboration to accelerate the development, manufacturing and clinical translation of Lu177-LT17, the company announced today.

“Our collaboration with LIFT reinforces NorthStar’s position as a preferred contract development and manufacturing partner across the radiopharmaceutical ecosystem, including with nonprofit and academic-led programs,” NorthStar President & CEO Dr. Frank Scholz said in a statement. “By combining our end-to-end CDMO capabilities with LIFT’s research model, we are helping bring promising new therapies closer to patients who need them most.”

According to a release, NorthStar will provide integrated radiopharmaceutical contract development and manufacturing (CDMO) capabilities, including LT17 isotope radiolabeling, analytical development and current Good Manufacturing Practice (cGMP) manufacturing support.

The partnership will support key translational and regulatory milestones aimed at supporting an Investigational New Drug (IND) application. Once that’s approved, NorthStar will manufacture the clinical supply for a planned Phase I trials.